Jefferies Downgrades IQVIA Holdings to Hold From Buy, Adjusts Price Target to $242 From $266
IQVIA Holdings: A Strong Buy on Robust R&D and Tech Growth Prospects
Deutsche Numis Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $275
Evercore Maintains IQVIA Holdings(IQV.US) With Buy Rating, Raises Target Price to $270
IQVIA Holdings Outperforms With Strong Q2 Results and Positive Growth Outlook: Cherny Maintains Buy Rating
Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Vertex Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Argenx Analyst Ratings
HSBC Adjusts Price Target on IQVIA to $290 From $280
BofA Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $275
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $251 to $300
Oppenheimer Upgrades Argenx SE to Outperform From Perform, $546 Price Target
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
Gilead Sciences (GILD) Receives a Buy From TD Cowen
Oppenheimer Upgrades Argenx SE(ARGX.US) to Buy Rating, Announces Target Price $546
Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $313
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85